5693-95-8Relevant articles and documents
Lewis acid enhanced axial ligation of [Mo2]4+ complexes
Dolinar, Brian S.,Berry, John F.
, p. 4658 - 4667 (2013/05/22)
We report here the syntheses, X-ray crystal structures, electrochemistry, and density functional theory (DFT) single-point calculations of three new complexes: tetrakis(monothiosuccinimidato)dimolybdenum(II) [Mo 2(SNO5)4, 1a], tetrakis(6-thioxo-2-piperidinonato) dimolybdenum(II) [Mo2(SNO6)4, 1b], and chlorotetrakis(monothiosuccinimidato)pyridinelithiumdimolybdenum(II) [pyLiMo2(SNO5)4Cl, 2-py]. X-ray crystallography shows unusually short axial Mo2-Cl bond lengths in 2-py, 2.6533(6) A, and dimeric 2-dim, 2.644(1) A, which we propose result from an increased Lewis acidity of the Mo2 unit in the presence of the proximal Li + ion. When 2-py is dissolved in MeCN, the lithium reversibly dissociates, forming an equilibrium mixture of (MeCNLiMo2(SNO5) 4Cl) (2-MeCN) and [Li(MeCN)4]+[Mo 2(SNO5)4Cl]- (3). Cyclic voltammetry was used to determine the equilibrium lithium binding constant (room temperature, K eq = 95 ± 1). From analysis of the temperature dependence of the equilibrium constant, thermodynamic parameters for the formation of 2-MeCN from 3 (ΔH = -6.96 ± 0.93 kJ mol-1 and ΔS = 13.9 ± 3.5 J mol-1 K-1) were extracted. DFT calculations indicate that Li+ affects the Mo-Cl bond length through polarization of metal-metal bonding/antibonding molecular orbitals when lithium and chloride are added to the dimolybdenum core.
A thionation process and a thionating agent
-
Page/Page column 9, (2012/08/14)
A process for transforming a group >C=O (I) in a compound into a group >C=S (II) or into a tautomeric form of group (II) in a reaction giving a thionated reaction product, by use of crystalline P2S5·2 C5H5N as a thionating agent. A thionating agent which is crystalline P2S5·2 C5H5N.
THALIDOMIDE ANALOGS
-
Page/Page column 56-57, (2008/06/13)
Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-α) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.